Holly W. Smith

Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies

Rafael Ponce, Leslie W. Abad, Lakshmi Amaravadi et al. · Regulatory Toxicology and Pharmacology · 2009 · 264 citations

Allergy, Immunotoxicology, Medicine +10

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

Andrew C. Adams, Carolyn A. Halstead, Barbara C. Hansen et al. · PLoS ONE · 2013 · 166 citations · Full text

Direct Fgf21 Action, Metabolic Disorder, Pathology +23

Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA

Holly W. Smith, Anthony Butterfield, Deqin Sun · Regulatory Toxicology and Pharmacology · 2007 · 126 citations

Biochemistry, Medicine, Bioanalysis +11

Nonclinical Safety Biomarkers of Drug-induced Vascular Injury

Igor Mikaelian, Mark J. Cameron, Deidre A. Dalmas et al. · Toxicologic Pathology · 2014 · 46 citations

Immunology, Cardiovascular Toxicity, Inflammation +17

Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents

Richard A. Byrd, Steven D. Sorden, Thomas E. Ryan et al. · Endocrinology · 2015 · 31 citations · Full text

Focal C-cell Hyperplasia, Carcinogenicity Studies, Pathology +23